Pinetree Therapeutics Raises $47M for Oncology
Slice of Healthcare Team
11/03/2025
Key highlights
- $47 million raised in Series B financing
- Advancing AbReptor™ platform for oncology
- Targeting drug-resistant cancers
- Support from prominent investors
- Potential for novel therapeutic approaches
Source: PR Newswire
Notable Quotes
“ The AbReptor™ platform has repeatedly demonstrated durable activity across a broad range of RTK targets. ”
Ho-Juhn Song, Ph.D., Founder and CEO at Pinetree Therapeutics
“ We are excited to continue our partnership with Pinetree as they advance a highly differentiated platform. ”
Yohan Kim, Executive Director at DSC Investment
Why this matters
This funding marks a significant step for Pinetree Therapeutics in the competitive biotech landscape, enabling the advancement of innovative therapies that address critical unmet needs in oncology, particularly for patients facing drug-resistant cancers. This development is particularly significant for the healthcare sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
